Larimar Therapeutics (LRMR) Research & Development (2013 - 2026)
Larimar Therapeutics' Research & Development came in at $28 million for Q2 2026, up 19.8% from $23.37 million a year earlier.
Powered by 
Analysis
Larimar Therapeutics (LRMR) Research & Development (2013 - 2026) Analysis & Trends
Over the trailing twelve months to Jun 30, 2026, Larimar Therapeutics reported Research & Development of $155.67 million, up 71.9% year-over-year; for FY2025, it was $154.22 million, up 110.5% from FY2024.
- Research & Development has increased in each of the last three years, with a five-year compound annual growth rate of 37.5% (FY2020 to FY2025).
- Going back by year, Research & Development was $73.28 million in FY2024 (+164.8%), $27.67 million in FY2023 (+14.1%), $24.25 million in FY2022 (-36.8%) and $38.4 million in FY2021 (+22.3%).
- The five-year range for quarterly Research & Development is $4.56 million (Q1 2023) to $59.37 million (Q4 2025).
- The fastest year-over-year change in Research & Development over five years came in Q2 2024 (growth of 235.0%), and the weakest in Q3 2022 (a decline of 60.2%).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,136.97 Bn | 1,105.55 Bn | 19.71 Bn | 3.82 Bn |
| 2 | Johnson & Johnson | 619.72 Bn | 538.25 Bn | 17.26 Bn | 3.65 Bn |
| 3 | AbbVie | 503.40 Bn | 476.52 Bn | 12.70 Bn | 2.34 Bn |
| 4 | Merck | 370.15 Bn | 324.53 Bn | 12.21 Bn | 9.74 Bn |
| 5 | Novartis Ag | 298.64 Bn | 262.63 Bn | 11.24 Bn | 2.85 Bn |
| 6 | Astrazeneca | 261.07 Bn | 234.76 Bn | 12.86 Bn | 4.05 Bn |
| 7 | Amgen | 237.00 Bn | 192.40 Bn | 7.24 Bn | 1.87 Bn |
| 8 | Gilead Sciences | 191.24 Bn | 165.43 Bn | 6.22 Bn | 1.76 Bn |
| 9 | Pfizer | 170.31 Bn | 116.96 Bn | 10.94 Bn | 2.81 Bn |
| 10 | Larimar Therapeutics | 252.95 Mn | -354.12 Mn | - | 28.00 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 28.00 Mn |
| Dec 31, 2025 | 59.37 Mn |
| Sep 30, 2025 | 44.93 Mn |
| Jun 30, 2025 | 23.37 Mn |
| Mar 31, 2025 | 26.55 Mn |
| Dec 31, 2024 | 26.74 Mn |
| Sep 30, 2024 | 13.92 Mn |
| Jun 30, 2024 | 19.68 Mn |
| Mar 31, 2024 | 12.94 Mn |
| Dec 31, 2023 | 10.65 Mn |
| Sep 30, 2023 | 6.59 Mn |
| Jun 30, 2023 | 5.88 Mn |
| Mar 31, 2023 | 4.56 Mn |
| Dec 31, 2022 | 7.22 Mn |
| Sep 30, 2022 | 5.58 Mn |
| Jun 30, 2022 | 5.64 Mn |
| Mar 31, 2022 | 5.81 Mn |
| Dec 31, 2021 | 6.29 Mn |
| Sep 30, 2021 | 14.03 Mn |
| Jun 30, 2021 | 9.10 Mn |
API Access
Larimar Therapeutics Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=LRMR&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "LRMR", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=LRMR&period=max&api_key=YOUR_API_KEY");
const data = await res.json();